Pharmaceutical giant Merck KGaA has agreed to buy Pfizer spinout SpringWorks Therapeutics for approximately $3.9 billion, marking a significant expansion in its oncology portfolio.
Source: https://endpts.com/merck-kgaa-to-buy-rare-cancer-biotech-springworks-for-3-9b